Harmony Biosciences Posts 81-Cent Q3 EPS
HRMY sits 41% above its 52-week low of $25.902.
Summary
Harmony Biosciences reported third-quarter earnings of 81 cents a share, per Dow Jones, on revenue of $268.9 million, a figure that missed estimates as profit fell on royalty charges to net income of USD 48.196 Million. That follows a record Q2 in which revenue hit $261.3 million, up 30%, and net income of $75.4 million nearly doubled year over year, so the bar was already high. The company said it is on track to achieve more than $1 billion in Wakix net revenue and announced strong multiple-ascending dose data for its orexin agonist BP-205, supporting a potential best-in-class profile. The print lands as the company works through CEO succession — COO Peter Anastasiou takes over January 1 — and awaits a ruling in the Wakix ANDA patent case against AET Pharma after October closing arguments. The pitolisant GR NDA has an April 2027 PDUFA date, keeping a second regulatory catalyst on the calendar.
At the time of this announcement, HRMY was trading at $36.50 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.2B. The 52-week trading range was $25.90 to $43.49. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.